ArticleEuropean journal of obstetrics & gynecology and reproductive biology: X2026
Cord blood procalcitonin and soluble urokinase-type plasminogen activator receptor in predicting histological chorioamnionitis - A pilot study.
Article in European journal of obstetrics & gynecology and reproductive biology: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Chorioamnionitis, caused by microbial invasion of amniotic cavity or sterile inflammation, can lead to prematurity and cytokine storm of fetus known as fetal inflammatory response syndrome (FIRS). Histological chorioamnionitis (HCA) on fetal side of placenta is a surrogate to FIRS. Cord blood (CB) reflects intrauterine inflammation. Our aim was to evaluate if more novel biomarkers procalcitonin (PCT) and soluble urokinase- type Plasminogen Activator Receptor (suPAR) were useful for identifying fetuses/neonates with high risk for FIRS/HCA. Methods: Twenty two women with a clinically confirmed preterm premature rupture of membranes (PPROM) or a suspicion of chorioamnionitis without PPROM (uterine tenderness, maternal fever ≥38°C, leukocytosis, fetal tachycardia ≥160 beats/minute) were enrolled at gestational weeks 23 Results: The cord blood concentration of IL-6 was significantly higher (p = 0.01) and had the best predictability for fetal side HCA (AUC 0.96, p = 0.03). Cord blood concentrations of PCT tended to be higher (p = 0.05), and to show significance for predicting fetal-side HCA (AUC 0.91, p = 0.07). No significant findings were found for suPAR. Conclusion: Cord blood IL-6 had the best ability to predict fetal side HCA. Cord blood PCT may be a promising biomarker. There were no significant findings for cord blood suPAR, suggesting its limited value as a biomarker in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.